NEW YORK (TheStreet) -- CHANGE IN RATINGS
were downgraded to neutral at UBS. The company's premium valuation is less warranted given specialty distribution will be less likely to drive superior EPS growth vs. peers, UBS said.
was upgraded at Nomura to neutral from reduce. $6 price target. PRB and Leer ramp warrant neutral rating post selloff, Nomura said.
was downgraded at Mizuho from buy to hold. $18 price target. Recent checks suggest that the company lacks near-term catalysts, Mizuho said.
was initiated with an underperform rating at DA Davidson. $28 price target. Stock is already pricing in a full housing recovery, DA Davidson said.
was upgraded at Nomura to neutral from reduce. $22 price target. Cost challenges are well-known, and PRB to inflect higher, Nomura said.
was downgraded to underperform from neutral at Credit Suisse. News that the company will form an MLP will not prove accretive until 2015, Credit Suisse said. Price target is $22.
was upgraded to buy from hold at Jefferies. $56 price target. Hospital industry should benefit from health care reform, Jefferies said.
was upgraded to buy at TheStreet Ratings.
was downgraded to neutral at UBS. Also, its price target was reduced to $27. The call is related to the stock's recent run and comes as the government's focus on Medicare payment outlook intensifies, UBS said.
was upgraded at Jefferies to buy. $14.50 price target. Company can continue recent momentum, given health care reform issues, Jefferies said.
was upgraded at Morgan Stanley to overweight. $27 price target. Free cash flow is growing and should exceed net income, Morgan Stanley said.
was upgraded to hold at TheStreet Ratings.
was downgraded at Goldman Sachs to sell from neutral. Company likely will see decelerating growth, Goldman said. $90 price target.
was upgraded at Jefferies to buy. Increased estimates reflect faster, longer methanol peak, Jefferies said. New price target is $54.
was upgraded at Keybanc to buy from hold. $4.80 price target. OMX merger will likely have material synergies, Keybanc said.
was upgraded at Goldman Sachs to buy from neutral. $11 price target. Company can continue to expand margins over the coming quarters, Goldman said.
was downgraded at UBS to neutral on valuation. The price target was raised to $34.70, UBS said.
was downgraded at Goldman Sachs to sell from neutral. $93 price target. Company is facing a negative inflection point in organic sales growth, Goldman said.
was upgraded at Needham to buy from hold. $52 price target. Company is leveraged to lower notebook demand and has limited visbility at Samsung, Needham said.
was downgraded to market perform from outperform at Wells Fargo. Company is facing increased competition and price erosion in the generic market, Wells Fargo said.
was upgraded at Citigroup to buy. The company's late-cycle positioning is key, and the valuation vs. peers is attractive, Citigroup said. New price target is $110.
was upgraded at Jefferies to buy. The company should capture a bigger share of the market with its more integrated model, Jefferies said. New price target is $35.
was upgraded at Citigroup to buy. There is now an increased likelihood that Verizon could buy out
, Citigroup said. New price target is $110.
STOCK COMMENTS/EPS CHANGES
numbers were cut at Wells Fargo. Shares are now seen reaching $12 to $13. Estimates were also lowered on mature store base of core business, Wells Fargo said. Market Perform rating.
price target and estimates were reduced at Credit Suisse. Rising costs related to Triumph and limited visibility will impact earnings, Credit Suisse said. Price target is $34.
Carnival price target and estimates were reduced at UBS. Earnings estimates were reduced through 2014. Europe demand is incrementally weaker since December, and Triumph impacted bookings, UBS said. Price target is $38.
price target raised at FBR Capital Markets. Shares are now seen reaching $225. Company appears to have a bigger business opportunity in the public sector, FBR Capital Markets said. Outperform rating.
Kraft Foods Group
( KFT) numbers were raised at Goldman Sachs. Shares are now seen reaching $51. Estimates also increased on K cups and costs, Goldman said. Neutral rating.
price target was boosted at Oppenheimer. Shares are now seen reaching $40. Company should maintain its growth trajectory, Oppenheimer said. Outperform rating.
price target was raised at Lazard Capital Markets. Shares are now seen reaching $74. Company has a deep pipeline of sales growth drivers, Lazard Capital Markets said. Buy rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.